Medivir AB (MVR0)

Overview

Medivir AB (publ) is a pioneering pharmaceutical company with a sharp focus on developing and commercializing innovative treatments for cancer. Serving the Nordic region, the rest of Europe, and markets internationally, Medivir operates with a commitment to addressing unmet medical needs in oncology. Since its inception in 1987, the company has positioned itself at the forefront of cancer therapy research and development. Based in Huddinge, Sweden, Medivir’s dedication to improving patient outcomes drives its quest for discovering novel treatments for various forms of cancer.

Products and Services

Xerclear/Zoviduo: This marketed product signifies Medivir’s ability to address viral infections, specifically labial herpes. Xerclear, known under the name Zoviduo in certain markets, offers patients effective treatment options for managing this common yet troubling condition.

Remetinostat: Currently in development, Remetinostat is aimed at treating cutaneous T-cell lymphoma (CTCL), focusing on Mycosis Fungoides (MF), basal cell carcinoma, and squamous cell carcinoma. This targeted therapy demonstrates Medivir’s expertise in tackling hard-to-treat cancers through innovative approaches.

MIV-818: Medivir is developing MIV-818 for the treatment of liver cancer, a formidable challenge in the oncology field. This investigational drug highlights the company’s relentless pursuit of new therapies to improve survival rates and quality of life for those affected by this challenging disease.

MIV-711: Tackling the widespread condition of osteoarthritis, MIV-711 is another therapeutic candidate in Medivir’s robust pipeline. By focusing on this degenerative joint disease, Medivir underscores its commitment to expanding its impact beyond oncology, addressing significant areas of patient need.

Birinapant and IGM-8444: These candidates are part of Medivir’s exploration into treatments for solid tumors. By advancing these investigational drugs, Medivir aims to broaden its oncology portfolio, offering hope to patients facing these prevalent cancer types.

USP-1/TNG348, USP-7, and MBLI/MET-X: These compounds have completed preclinical trials, showcasing Medivir’s ability to innovate in the space of cancer and infection treatment. While still in early development stages, these projects reflect the company’s dynamic approach to discovering new pathways and targets in the fight against cancer.